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Abstract
Introduction The aim of the study was to analyse pH- and bile-monitoring data in patients with Barrett’s esophagus and in
age- and gender-matched controls.
Subjects and Methods Twenty-four consecutive Barrett’s patients (8 females, 16 males, mean age 57 years), 21 patients
with esophagitis (10 females, 11 males, mean age 58 years), and 19 healthy controls (8 females, 11 males, mean age
51 years), were included. Only patients underwent endoscopy with biopsy. All groups were investigated with manometry,
gastric and esophageal 24-h pH, and simultaneous bile monitoring according to a standardized protocol. A bilirubin
absorption >0.25 was determined as noxious bile reflux. The receiver operator characteristic (ROC) method was applied to
determine the optimal cutoff value of pathologic bilirubin levels.
Results Of Barrett’s patients, 79% had pathologic acidic gastric reflux (pH<4 >5% of total measuring time). However, 32%
of healthy controls also had acid reflux (p<0.05) without any symptoms. The median of esophageal bile reflux was 7.8%
(lower quartile (LQ)–upper quartile (UQ)=1.6–17.8%) in Barrett’s patients, in patients with esophagitis, 3.5% (LQ–UQ=
0.1–13.5), and in contrast to 0% (LQ–UQ=0–1.0%) in controls, p=0.001. ROC analysis showed the optimal dividing
value for patients at more than 1% bile reflux over 24 h (75% sensitivity, 84% specificity).
Conclusion An optimal thresholdto differentiate between normalandpathological bile refluxinto the esophagus is 1%(24-hbile
monitoring with an absorbance >0.25).
Keywords Reference valuebilitec.Bilereflux.
Acidreflux.Barrett’smucosa.Esophagus.
Spectrophotometry
Introduction
The incidence rates for adenocarcinoma (AC) of the
esophagus and gastric cardia have risen rapidly in
Western industrialized countries.
1 Besides nicotine and
alcohol abuse, nutritional factors, high body mass index,
acidic gastric reflux, and Barrett’s esophagus are believed
to be critical factors of carcinogenesis.
2–4 Recent studies
have shown that the presence of biliary reflux in
combination with acidic gastric reflux damages the
esophageal mucosa and causes complications of gastro-
esophageal reflux disease (GERD), e.g., development of
Barrett’s mucosa (BM).
5,6 Duodeno-gastric reflux into the
esophagus (DGER), in particular, appears to be important
to the pathogenesis of Barrett’s esophagus.
7 Prolonged
esophageal aspiration studies have documented increased
bile acids in patients with severe esophagitis and Barrett’s
esophagus.
8 Eighty percent of patients with Barrett’s
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e-mail: Elfriede.bollschweiler@uk-koeln.deesophagus on proton-pump inhibitors show a normal
esophageal pH profile, but 60% show abnormal esopha-
geal exposure to bile as measured by Bilitec 2000.
9
In the past, direct and prolonged quantification of
duodenoesophageal reflux has been difficult to achieve.
Now, bilirubin concentration can be directly measured by
spectrophotometry, based on the specific absorption at a
wavelength of 453 nm. Biliary reflux can be measured with
a transnasally passed, ambulatory fiberoptic probe (Bilitec
2000), which records bile absorption. A number of papers
have already been published on the exposure of the
esophagus
10–13 and stomach
14–16 using this technique.
However, in these studies, the control patients were
between 25 and 35 years old. In clinical practice, patients
with Barrett’s mucosa tend to be older. In addition, the
authors of each study used varying reference values to
measure biliary reflux in the esophagus, making compari-
son of the measured values difficult.
The aim of the present study was to analyze data of pH and
bile monitoring in a collective of healthy age- and gender-
matched controls and patients with Barrett’s esophagus.
Subjects and Methods
Subjects
Selection of controls was carried out according to a strict
protocol. Healthy volunteers treated from 1999 to 2000
between the ages of 40 and 60 years were included in the
study. None of the controls were on acid suppressing or gut
motility medications, had a history of upper gastrointestinal
disease, had undergone upper or major abdominal surgery,
or had had therapeutic endoscopic procedures of the upper
gastrointestinal tract. Diagnostic endoscopy and barium
swallows were not performed, but gallstone disease was
excluded by ultrasound scan.
From 1999 to 2002, 24 patients with histologically
confirmed Barrett’s mucosa were included in the study. For
additional comparison, we include a group of patients with
esophagitis (stage I to III according Savary and Miller)
without Barrett’s esophagus, which had the same diagnostic
procedures before planned laparoscopic fundoplication.
During the aforementioned time span, 21 patients age older
than 40 years were available for this study. Exclusion
criteria were history of esophageal, gastric, or biliary
surgery, history of abdominal or thoracic radiotherapy, or
presence of peptic ulcer disease, active gastrointestinal
bleeding, esophageal or fundic varices, esophageal or upper
small intestine chronic disease, or neoplastic disease. All
drugs potentially affecting gastrointestinal motility and
secretion were discontinued at least 1 week before the
study.
Upper Gastrointestinal Endoscopy
All patients underwent classical upper gastrointestinal
endoscopy. If sedation was necessary, intravenous admin-
istration of propofol (up to 200 mg) was normally used, or
occasionally, midazolam (up to 5 mg) was used. During
endoscopy, the presence and extent of esophagitis, Barrett’s
esophagus, and hiatal hernia was noted. Biopsies were
taken from the Barrett’s mucosa.
Ambulatory Esophageal/Gastric pH and Bile Monitoring
All groups underwent esophageal manometry and 24-h pH
and simultaneous bile monitoring using a standardized
protocol. Ambulatory pH monitoring was performed using
atransnasallyinsertedantimonypHelectrode withaseparate
skin reference electrode (Synetics Medical, Stockholm,
Sweden). The data were stored on a portable digital recorder
(Digitrapper MkIII, Synectics Medical Stockholm, Sweden).
Before each study, the pH probe was calibrated in buffer
solutions of pH 7 and 1. An episode of acid reflux was
defined as a decrease in esophageal pH to less than 4 for
more than 10 s.
To quantify duodeno-esophageal reflux, a transnasally
passed, ambulatory fiberoptic spectrophotometer (Bilitec
2000, Synectics, Sweden) was used. The system consists of
a miniaturized probe of 1.5-mm diameter that carries light
signals into the esophagus and back via a plastic fiberoptic
bundle. Before each study, the probe was calibrated in
water. Corresponding to the current literature, a bilirubin
absorption >0.25 was used as a reference for noxious
biliary reflux.
14
The bile and pH probes were taped together and passed
transnasally into the esophagus and stomach, as described
in detail elsewhere.
17 The upper tips of the probes were
positioned 5 cm above the upper border of the lower
esophageal sphincter as defined by esophageal manometry.
The distal pH electrode and fiberoptic sensor were placed in
the fundus of the stomach, 10 cm distal to the lower
esophageal sphincter (Fig. 1). Controls and patients were
asked to follow a strict protocol of three meals per day, with
no liquids between meals. Recumbent phases of recording
were permitted only at night. Patients were asked to keep a
diary recording of the exact nature of meals, the supine and
erect phases of measurement, and the sensations of
heartburn and regurgitation.
The simultaneous biliary and pH monitoring was done
with administration of a colorless “white diet” (WD)
including liquid and solid foods with a maximum in vitro
bile absorbance of 0.25 [absorbance scale ranging from 0
(plain water) to 1 (total screen)]. The meals included
water, milk, toast, potatoes, chicken, dry biscuits, and
fish.
480 J Gastrointest Surg (2007) 11:479–486Data Acquisition and Interpretation
After completion of the measurements, probes were
withdrawn from the patients, and data were stored via
interface on an IBM-compatible computer equipped with
Polygram® software (Medtronic). The data of each second
of the 24-h measurements were used for analysis. To assess
the presence of gastric or esophageal biliary reflux, the
percentage of time when absorbance was greater than 0.25
was calculated for the following periods: total supine,
upright, and postprandial. The postprandial period was
defined as 2 h after the end of meals. The percentage of
time with esophageal pH lower than 4 and median gastric
pH and the percentage of time with gastric pH measuring 1,
2, 3–7, and >7 was also calculated for the above periods.
The mean duration of the ambulatory pH and Bilitec
monitoring study was 22 h, 40 min in patients and 23 h,
44 min in the controls.
Statistical Analysis
The SPSS (version 11.0, Chicago, Illinois) program was
used to analyze the results. For graphical presentation, we
used the program MedCalc for Windows, (Version 9.0,
MedCalc Software, Belgium). Median, interquartile range
(IQR or 25th to 75th percentile) values were established.
The nonparametric tests (Mann–Whitney and Kruskal–
Wallis analysis) were used to assess the relationship
between variables. Box and Whisker plots were used to
present some of the data. In these plots, the box represents
the IQR, and the Whiskers represent the highest and lowest
values. Outliers are also plotted, defined as more than 1.5
times the IQR from the 75th centile. Extreme values were
defined as more than three times the IQR from the 75th
centile.
A receiver operator characteristic (ROC) curve was used
to find a cutoff value for optimal sensitivity and specificity
according Zweig and Campbell.
18 The area under the curve
(AUC) as a measurement of diagnostic performance of the
test was used. The results are given as point with the 95%
confidence interval (95% CI) and graphically for presenta-
tion of all data. As the positive group, we used the patients
with Barrett’s mucosa, and the negative test group was
defined by the healthy volunteers. A nonparametric
distribution of the area under the curve was assumpted.
The assumptions for calculation of the required sample
size were alpha=0.05, beta=0.80, and that a test is only
valid for daily use if less than 20% of the healthy controls
and at least 80% of the patients have positive test results.
The calculated sample size for each group was 20.
Ethics
The study protocol was approved by the ethics committee
of the University of Cologne. Each subject gave written
informed consent.
Results
Twenty-four patients with Barrett’s esophagus (mean age:
58 years), 21 patients with esophagitis (mean age: 57 years),
and 19 healthy controls with a mean age of 51 years were
included in the study. Patients with BM showed esophagitis
grade 0 (4 cases), grade I (12 cases), and grade II (8 cases).
The control group of patients with esophagitis showed nine
cases with grade I, eight cases with grade II, and three cases
with grade III. Demographics of patients and volunteers are
displayed in Table 1 (the data of one volunteer was not
usable due to technical problems).
Acidic Gastric Reflux (AGR)
Patients with Barrett’s esophagus, 19 of 24 (79%) and 20 of
21 control patients with esophagitis (95%) had pathologic
AGR [pH<4 in >5% of total measuring time (TMT)], but
also 6 of the 19 healthy controls (32%) showed pathologic
AGR without any symptoms (p=0.002). During the TMT,
the median AGR was 10.6% for Barrett patients and 3.2%
for controls (p<0.01). In particular, measurements of long
acid reflux (LAR), defined as reflux pH<4 lasting longer
than 5 min, showed significant differences between patients
and controls. Pathologic AGR was found in patients during
Figure 1 Position of the pH- and bilirubin-probes in the stomach and
in the esophagus. (UES=upper esophageal sphincter; LES=lower
esophageal sphincter).
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contrast, pathologic AGR in healthy controls occurred only
in the upright position (Table 2).
24-h Intragastric pH and Bile Monitoring
Gastric pH monitoring showed no significant differences
between patients and controls for all measuring periods
(Table 3). Gastric bilirubin exposure, indicating biliary
reflux, was significantly more frequent in patients than in
controls during all measuring periods (Table 3). Biliary
exposure in the supine position typically occurred during
the early hours of the morning during sleep, represented by
increased absorbance over 2–3 h, with a rapid return to
baseline values around the time the subject resumed the
upright position. Over the same time period, gastric pH
monitoring showed increased pH levels to greater than 2
(Fig. 2).
Bilirubin Exposure of the Esophagus
Over the TMT, the median of esophageal biliary reflux was
7.8% for patients with Barrett’s esophagus (LQ–UQ=1.6–
17.8%) and 3.5 (LQ–UQ=0.1–13.5) for control patients, in
contrast to 0% for the controls (LQ–UQ=0–1.0%), p=
0.001). Figure 3 shows that esophageal bile monitoring in
patients with Barrett’s esophagus and healthy controls
varied during the total measuring and supine periods.
The receiver operating curve, plotting the true positive
rate (patients with Barrett’s esophagus identified by
bilirubin exposure) in function of the false positive rate
(healthy controls with high bilirubin exposure) is shown in
Fig. 4. With an area under the curve of 0.78 (95% CI=
0.56–0.89), the ROC analysis of biliary monitoring showed
the optimal value for patients at 1% of the TMT [75%
sensitivity (95% CI=53–90%), 84% specificity (95% CI=
60–96%)]. Therefore, the cutoff value to distinguish
normal vs pathologic biliary reflux using 24-h biliary
monitoring in the esophagus (absorbance threshold >0.25)
should be fixed at 1% of TMT.
Barrett patients, 18 of 24 (75%), 15 of 21 control
patients with esophagitis (71%), and 3 of 19 controls (16%)
showed biliry reflux into the esophagus more than 1.1% of
the TMT (p<0.001). Using this cutoff value, none of the
controls, 10 of the control patients (48%), and 11 of 24
Barrett’s patients (46%) had pathologic bilirubin exposure
during sleep.
Discussion
The results of our study confirm that patients with Barrett’s
esophagus have significantly more frequent duodenogastric
reflux into the esophagus than age- and sex-matched
healthy controls. In addition, this reflux, measured by acid
and bilirubin exposure, remains longer in the esophagus,
especially during sleep.
The role of acid and nonacid reflux into the esophagus
as a causative factor of symptoms and mucosal lesions has
been addressed in a number of studies. Not only the
Table 2 Median of Acidic Gastric Reflux into the Esophagus in Patients with BM or with Esophagitis and in Healthy Controls
Parameters Patients with Barrett’s
Esophagus (n=24)
[median (LQ-UQ)]
Patients with
Esophagitis (n=21)
[median (LQ-UQ)]
Controls (n=19)
[median (LQ-UQ)]
Significance Pat.
with Barrett vs
Controls
Percentage of total measuring time pH<4 (%) 10.6 (6.2–38.3) 19.9 (1.6–71.7) 3.2 (0.9–5.5) p=0.01
Percentage of upright measuring time pH<4 (%) 11.7 (6.03–6.4) 18.9 (8.7–60.8) 2.4 (0.9–6.1) p<0.05
Percentage of supine measuring time pH<4 (%) 10.9 (0.4–27.1) 6.3 (0.0–13.3) 0.3 (0.0–4.2) p=0.004
LQ Lower quartile, UQ upper quartile
Table 1 Demographic Data of Patients with Barrett-Mucosa or Esophagitis and Healthy Volunteers
Parameters Patients with Barrett’s
Esophagus (n=24)
Patients with Esophagitis
(n=21)
Controls (n=19) Significance Pat.
with Barrett vs
Controls
Age (median) 57 years 58 years 51 years –
Min–max 29–75 years 42–77 years 39–62 years
Gender m:f 16:8 11:10 11:8 n.s.
BMI (median) min–max 27.0 kg/m
2 (18.6–33.1) 26.9 kg/m
2 (17.9–31.5) 24.1 kg/m
2 (19.62–27.34) p=0.003
Smokers (%) n=5 (20.8) n=4 (19.0) n=6 (31.6) n.s.
No alcohol % n=3 (12.5) n=5 (23.8) n=5 (26.3) n.s.
BMI Body mass index
482 J Gastrointest Surg (2007) 11:479–486duration, but possibly the composition of the reflux, is
instrumental in the development of such lesions.
13
Twenty-four-hour intragastric bile monitoring has provided
the clinician with unequivocal evidence of excessive
duodenogastric reflux (DGR) in 41% of patients with
endoscopic esophagitis, gastroesophageal reflux (GER)
symptoms, and gastric symptoms suggestive of DGR.
19
Reflux of duodenal contents into the stomach, especially
postprandially, is a physiological event;
20 however, biliary
reflux is a large contributor to mucosal lesions in the whole
stomach.
21
In our study, the control group of patients with different
grades of esophagitis showed no significantly different
measurements of acidic or bile reflux into the stomach or
the esophagus compared to Barrett’s patients. This may be
caused by selection of patients with esophagitis, which
were candidates for fundoplication, but both groups of
patients differed significantly compared to healthy controls.
Figure 2 24h intragastric pH- and bile monitoring in a patient with Barrett’s esophagus demonstrating the duodenogastric reflux in the early
morning. a. Bilitec®-monitoring, b. pH-monitoring.
Table 3 Results of 24-H Intragastric pH and Bile Monitoring in Patients with Barrett Esophagus and Healthy Controls
Parameters Patients (n=24)
[Median (LQ–UQ)]
Controls (n=19)
[Median (LQ–UQ)]
Significance
Median of intragastric pH during TMT 1.3 (1.0–1.4) 1.4 (1.1–1.7) n.s.
Bilirubin exposure percentage (%) of TMT 7.8 (1.6–17.8) 0.0 (0.0–1.0) p=0.001
Bilirubin exposure percentage (%) of upright time 6.9 (0.1–12.9) 0.0 (0.0–1.3) p<0.01
Bilirubin exposure percentage (%) of supine time 2.0 (0.0–28.6) 0.0 (0.0–0.0) p=0.001
LQ Lower quartile, UQ upper quartile, TMT total measuring time
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especially for preoperative diagnostic.
Marshall et al. compared healthy controls to patients
with different grades of reflux-esophagitis and Barrett’s
esophagus with regard to bile measurements in the
stomach.
22 In this study, the average age of the control
patients was 25 years, and that of the patients in Groups I,
II, and III was 42, 50, and 60 years, respectively. The
bilitec-probe was positioned 10 cm below the lower
esophageal sphincter (LES). The threshold of bilirubin
absorbance was 0.14, and although no difference was found
between groups over the TMT, gastric bilirubin exposure
was higher in the supine than in the upright position. In the
current study, the control group was older than that of the
Marshall study. More duodeno-gastric reflux was recorded
in both study and control patients during all periods of
measurement. These findings may be due to improved
study conditions.
We used an esophageal threshold of 0.25 for bilirubin
absorbance. Fein et al.,
14 in an in vitro study of absorption
of different white meals, showed that the least food
interference during bile monitoring was measured with an
absorbance > 0.25.
Tack et al. reported the influence of meal consistency on
Bilitec measurement results in healthy subjects.
23 They
compared two groups of young controls. The subjects took
either liquid meals only, not absorbing light of the same
wavelength as bilirubin, or solid food, avoiding diets that
interfere with bilirubin absorbance. The authors found
significant differences between the two groups using a
bilirubin absorbance threshold >0.14 with a median
percentage (interquartile range) over the TMT of 10.9 %
(6.7–19.3) for solid meals and 0.3% (0.0–2.8) for liquid
meals. Major meal artifacts were present in two-solid-meal
(10%) and no-liquid-meal subjects. In our study, we found
such a meal artifact in one patient and one control, but the
values of bilirubin absorbance were lower than 0.25, and
therefore, not relevant to our results.
It is not unusual for gastro-esophageal reflux to contain
bile, duodenal, and pancreatic secretions. Utilization of the
Bilitec spectrophotometric probe has demonstrated a higher
prevalence of abnormal esophageal bilirubin exposure in
patients with Barrett’s metaplasia when compared to those
with erosive injury or without signs of esophagitis.
6,8,10,13
In those studies, patients were consistently older than
volunteers included in the control group. However, other
studies have shown an increased prevalence of gastro-
esophageal reflux with age.
24 For these reasons, we studied
Figure 4 ROC-curve with 95% confidence intervals for pathologic
bile-monitoring in patients with Barrett esophagus compared to age
and sex matched healthy controls.
Figure 3 Results of the esophageal bile-monitoring in 24 patients
with Barrett’s esophagus, 21 patients with esophagitis and 19 healthy
controls a) total measuring period (Kruskal-Wallis Test=0.01) b)
supine period (Kruskal-Wallis Test p=0.01).
484 J Gastrointest Surg (2007) 11:479–486age and sex matched healthy controls and patients with
Barrett’s esophagus or with esophagitis. We found patho-
logic acid and biliary reflux of the esophagus in one-third
of the controls. Perhaps, this may be caused by artefacts or
by violation of the protocol by the volunteers. But in a
previous published study, we could show that younger
healthy controls had no such pathologic reflux.
17 Possibly,
these phenomena are caused by relaxations which occur
more often in older people. In contrast, nearly all patients
with Barrett’s esophagus (87%) and all patients with
esophagitis (100%) showed pathologic acidic reflux and/
or bile reflux measured with combined pH and bile
monitoring. Bile reflux into the esophagus during sleep, in
particular, was only found in patients with BM or with
esophagitis.
In our study, we measured the intragastric pH and the
bile reflux from the duodenum into the stomach (DGR).
The median of the intragastric pH was similar in both
groups. But patients with Barrett’s esophagus had signifi-
cantly longer duodenogastric reflux during the 24-h mea-
suring period than controls. More DGR was demonstrated
at night than during the day in both groups of study patients
and in healthy controls. This could be associated with an
alkaline shift in the pH, according to previously published
studies.
25–27 The precise mechanism by which nocturnal
DGR occurs and the roles posture plays remain unclear.
Bowrey et al. were unable to establish either gastro-
esophageal or duodenogastric reflux as the predominant
cause of inflammation in gastric cardiac mucosa with use of
the Bilitec 2000 device.
16 This is understandable, as the
amount of reflux into the stomach (DGR) does not
necessarily correlate with DGER into the esophagus. In
this study, the authors demonstrated more DGR in females
during the supine period, while males presented more
DGER. At the same time, there was no correlation between
bile levels in the stomach and esophagus. The controls
were, however, much younger than the patients. We found
significant differences in bile measurements of the stomach
and esophagus between BM patients and controls. In
contrast to Bowrey et al., we saw more DGER in females
during the supine period and more DGR in male patients.
In contrast, Banki reported similar esophageal exposure
to refluxed acid and bilirubin in females and in males with
Barrett’sm u c o s a .
28 Pfaffenbach et al.
29 studied esophageal
bile and acid reflux in patients with long segment Barrett’s
esophagus (LSBE), short segment Barrett’se s o p h a g u s
(SSBE) and patients with gastro-esophageal reflux disease
(GERD). Subjects underwent esophageal manometry and
simultaneous 24-h pH and bile monitoring (Bilitec 2000)
with an absorbance value >0.2 for 10.9% of the total
period. GER did not differ between the groups. However,
DGER differed between patients with LSBE (14.7%),
SSBE (2.1%), and GERD (2.1%).
In summary, the analysis of reference values of esoph-
ageal acid and bile-reflux measurements in a collective of
healthy, age- and gender-matched controls compared to
patients with BM led to the following conclusions:
1. Although about 30% of the healthy controls showed
acid reflux in pH monitoring, patients with BM had
significantly more acid reflux during all measured
periods.
2. Healthy controls did not have relevant duodeno-gastric-
esophageal reflux measured by bilirubin absorbance.
Especially during the supine period, there was no bile
reflux.
3. The optimal threshold for pathological bile reflux is 1.1
% (bile monitoring with an absorbance of 0.25).
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